PMID- 25099655
OWN - NLM
STAT- MEDLINE
DCOM- 20150616
LR  - 20211021
IS  - 1534-4681 (Electronic)
IS  - 1068-9265 (Print)
IS  - 1068-9265 (Linking)
VI  - 21
IP  - 10
DP  - 2014 Oct
TI  - Chemosensitivity predicted by BluePrint 80-gene functional subtype and MammaPrint 
      in the Prospective Neoadjuvant Breast Registry Symphony Trial (NBRST).
PG  - 3261-7
LID - 10.1245/s10434-014-3908-y [doi]
AB  - PURPOSE: The purpose of the NBRST study is to compare a multigene classifier to 
      conventional immunohistochemistry (IHC)/fluorescence in situ hybridization (FISH) 
      subtyping to predict chemosensitivity as defined by pathological complete 
      response (pCR) or endocrine sensitivity as defined by partial response. METHODS: 
      The study includes women with histologically proven breast cancer, who will 
      receive neoadjuvant chemotherapy (NCT) or neoadjuvant endocrine therapy. 
      BluePrint in combination with MammaPrint classifies patients into four molecular 
      subgroups: Luminal A, Luminal B, HER2, and Basal. RESULTS: A total of 426 
      patients had definitive surgery. Thirty-seven of 211 (18 %) IHC/FISH hormone 
      receptor (HR)+/HER2- patients were reclassified by Blueprint as Basal (n = 35) or 
      HER2 (n = 2). Fifty-three of 123 (43 %) IHC/FISH HER2+ patients were reclassified 
      as Luminal (n = 36) or Basal (n = 17). Four of 92 (4 %) IHC/FISH triple-negative 
      (TN) patients were reclassified as Luminal (n = 2) or HER2 (n = 2). NCT pCR rates 
      were 2 % in Luminal A and 7 % Luminal B patients versus 10 % pCR in IHC/FISH 
      HR+/HER2- patients. The NCT pCR rate was 53 % in BluePrint HER2 patients. This is 
      significantly superior (p = 0.047) to the pCR rate in IHC/FISH HER2+ patients (38 
      %). The pCR rate of 36 of 75 IHC/FISH HER2+/HR+ patients reclassified as 
      BPLuminal is 3 %. NCT pCR for BluePrint Basal patients was 49 of 140 (35 %), 
      comparable to the 34 of 92 pCR rate (37 %) in IHC/FISH TN patients. CONCLUSIONS: 
      BluePrint molecular subtyping reclassifies 22 % (94/426) of tumors, reassigning 
      more responsive patients to the HER2 and Basal categories while reassigning less 
      responsive patients to the Luminal category. These findings suggest that compared 
      with IHC/FISH, BluePrint more accurately identifies patients likely to respond 
      (or not respond) to NCT.
FAU - Whitworth, Pat
AU  - Whitworth P
AD  - Department of Surgery, Nashville Breast Center, Nashville, TN, USA, 
      patwhitworth@gmail.com.
FAU - Stork-Sloots, Lisette
AU  - Stork-Sloots L
FAU - de Snoo, Femke A
AU  - de Snoo FA
FAU - Richards, Paul
AU  - Richards P
FAU - Rotkis, Michael
AU  - Rotkis M
FAU - Beatty, Jennifer
AU  - Beatty J
FAU - Mislowsky, Angela
AU  - Mislowsky A
FAU - Pellicane, James V
AU  - Pellicane JV
FAU - Nguyen, Bichlien
AU  - Nguyen B
FAU - Lee, Laura
AU  - Lee L
FAU - Nash, Charles
AU  - Nash C
FAU - Gittleman, Mark
AU  - Gittleman M
FAU - Akbari, Stephanie
AU  - Akbari S
FAU - Beitsch, Peter D
AU  - Beitsch PD
LA  - eng
PT  - Journal Article
DEP - 20140807
PL  - United States
TA  - Ann Surg Oncol
JT  - Annals of surgical oncology
JID - 9420840
RN  - 0 (Biomarkers, Tumor)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Biomarkers, Tumor/*genetics/metabolism
MH  - Breast Neoplasms/*diagnosis/*drug therapy/genetics/metabolism
MH  - Drug Resistance, Neoplasm/*genetics
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - *Neoadjuvant Therapy
MH  - Neoplasm Grading
MH  - Neoplasm Staging
MH  - Prognosis
MH  - Prospective Studies
MH  - Receptor, ErbB-2/metabolism
MH  - Receptors, Estrogen/metabolism
MH  - Receptors, Progesterone/metabolism
MH  - Registries
MH  - Survival Rate
MH  - Young Adult
PMC - PMC4161926
EDAT- 2014/08/08 06:00
MHDA- 2015/06/17 06:00
PMCR- 2014/08/07
CRDT- 2014/08/08 06:00
PHST- 2014/04/14 00:00 [received]
PHST- 2014/08/08 06:00 [entrez]
PHST- 2014/08/08 06:00 [pubmed]
PHST- 2015/06/17 06:00 [medline]
PHST- 2014/08/07 00:00 [pmc-release]
AID - 3908 [pii]
AID - 10.1245/s10434-014-3908-y [doi]
PST - ppublish
SO  - Ann Surg Oncol. 2014 Oct;21(10):3261-7. doi: 10.1245/s10434-014-3908-y. Epub 2014 
      Aug 7.